Clinical Updates and Perspectives in VMS Management

Fiona C. Baker, PhD, outlines the NIRVANA study’s design and goals, noting its focus on evaluating elinzanetant’s impact on vasomotor symptoms and sleep-related outcomes.

Fiona C. Baker, PhD, reviews NIRVANA’s findings showing early onset of relief for both VMS and sleep disturbances, supported by patient-reported improvements in sleep quality, duration, and nighttime awakenings.

Fiona C. Baker, PhD, emphasizes the importance of patient-reported outcomes in assessing elinzanetant’s overall benefit, including insights on symptom recurrence and quality-of-life improvements.

Fiona C. Baker, PhD, compares elinzanetant with current therapeutic options, noting how its profile aligns with the needs of patients experiencing both VMS and sleep disturbances.

Fiona C. Baker, PhD, discusses the interconnected nature of VMS and sleep disturbances, stressing why treating both together—and achieving rapid symptom relief—is key for patient satisfaction.

Fiona C. Baker, PhD, summarizes the most clinically relevant takeaways from NIRVANA and explores how these findings may shape future treatment decisions and guideline conversations.